PD-L1 in squamous cell carcinoma of the oral tongue shows gender-specific association with prognosis.
PD-L1
SCCOT
gender
Journal
Oral diseases
ISSN: 1601-0825
Titre abrégé: Oral Dis
Pays: Denmark
ID NLM: 9508565
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
19
02
2020
revised:
11
04
2020
accepted:
02
05
2020
pubmed:
15
5
2020
medline:
22
12
2020
entrez:
15
5
2020
Statut:
ppublish
Résumé
To use alternative quantitation approaches to clarify the clinical implication of programmed cell death ligand 1 (PD-L1) in squamous cell carcinoma of the oral tongue (SCCOT). Ventana SP263 immunohistochemistry assay and a multiplicative QuickScore method were applied to quantify PD-L1 in tumor and surrounding immune cells from 101 patients with SCCOT. Tumor-infiltrating immune cells were estimated from bulk tissue transcriptional profiles of 25 patients. Circulating PD-L1 levels were measured in serum from 30 patients using an electrochemiluminescence assay platform. We found higher tumor cell PD-L1 levels in females than males (p = .019). For patients with low PD-L1 in tumor cells, better survival was seen in males than females (overall survival p = .021, disease-free survival p = .020). Tumor-infiltrating natural killer T cells, immature dendritic cells, and M1 macrophages were positively associated with tumor cell PD-L1 (p < .05). Our data confirmed the significance of gender on tumor cell PD-L1 expression and demonstrated combined effects of gender and PD-L1 levels on clinical outcome in patients with SCCOT. The data also indicated the involvement of specific immune cell types in PD-L1-regulated immune evasion.
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Types de publication
Journal Article
Langues
eng
Pagination
1414-1423Subventions
Organisme : Ministry of Education Youth and Sports in the Czech Republic
ID : project MEYS-NPSI-LO1413
Organisme : The Swedish Cancer Society
ID : contract number 18 0542
Organisme : Umeå Universitet
Organisme : Lion's Cancer Research Foundation, Umeå University
Organisme : Region Västerbotten
Organisme : Grantová Agentura České Republiky
ID : project P206/12/G151
Informations de copyright
© 2020 The Authors. Oral Diseases published by John Wiley & Sons Ltd.
Références
Aran, D., Hu, Z., & Butte, A. J. (2017). xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biology, 18(1), 220. https://doi.org/10.1186/s13059-017-1349-1
Biswas, S. K., & Mantovani, A. (2010). Macrophage plasticity and interaction with lymphocyte subsets: Cancer as a paradigm. Nature Immunology, 11(10), 889-896. https://doi.org/10.1038/ni.1937
Boldrup, L., Coates, P. J., Laurell, G., & Nylander, K. (2011). Differences in p63 expression in SCCHN tumours of different sub-sites within the oral cavity. Oral Oncology, 47(9), 861-865. https://doi.org/10.1016/j.oraloncology.2011.07.002
Boldrup, L., Coates, P. J., Wahlgren, M., Laurell, G., & Nylander, K. (2012). Subsite-based alterations in miR-21, miR-125b, and miR-203 in squamous cell carcinoma of the oral cavity and correlation to important target proteins. Journal of Carcinogenesis, 11, 18. https://doi.org/10.4103/1477-3163.104007
Boldrup, L., Gu, X., Coates, P. J., Norberg-Spaak, L., Fahraeus, R., Laurell, G., … Nylander, K. (2017). Gene expression changes in tumor free tongue tissue adjacent to tongue squamous cell carcinoma. Oncotarget, 8(12), 19389-19402. https://doi.org/10.18632/oncotarget.14288
Boldrup, L., Troiano, G., Gu, X., Coates, P., Fahraeus, R., Wilms, T., … Nylander, K. (2017). Evidence that circulating proteins are more promising than miRNAs for identification of patients with squamous cell carcinoma of the tongue. Oncotarget, 8(61), 103437-103448. https://doi.org/10.18632/oncotarget.21402
Brandwein-Gensler, M., Teixeira, M. S., Lewis, C. M., Lee, B., Rolnitzky, L., Hille, J. J., … Wang, B. Y. (2005). Oral squamous cell carcinoma: Histologic risk assessment, but not margin status, is strongly predictive of local disease-free and overall survival. American Journal of Surgical Pathology, 29(2), 167-178. 00000478-200502000-00003
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394-424. https://doi.org/10.3322/caac.21492
Burtness, B., Harrington, K. J., Greil, R., Soulieres, D., Tahara, M., de Castro, G., & Yorio, J.. (2019). Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet, 394(10212), 1915-1928. https://doi.org/10.1016/S0140-6736(19)32591-7
Cancer Genome Atlas N (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517(7536), 576-582. https://doi.org/10.1038/nature14129
Capone, I., Marchetti, P., Ascierto, P. A., Malorni, W., & Gabriele, L. (2018). Sexual dimorphism of immune responses: A new perspective in cancer immunotherapy. Frontiers in Immunology, 9, 552. https://doi.org/10.3389/fimmu.2018.00552
Chen, D. S., & Mellman, I. (2013). Oncology meets immunology: The cancer-immunity cycle. Immunity, 39(1), 1-10. https://doi.org/10.1016/j.immuni.2013.07.012
Cho, Y. A., Yoon, H. J., Lee, J. I., Hong, S. P., & Hong, S. D. (2011). Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma. Oral Oncology, 47(12), 1148-1153. https://doi.org/10.1016/j.oraloncology.2011.08.007
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., … Seiwert, T. Y. (2016). Antitumor activity of pembrolizumab in biomarker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. Journal of Clinical Oncology, 34(32), 3838-3845. https://doi.org/10.1200/JCO.2016.68.1478
Cohen, E. E. W., Soulieres, D., Le Tourneau, C., Dinis, J., Licitra, L., Ahn, M. J., … Zandberg, D.. (2019). Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet, 393(10167), 156-167. https://doi.org/10.1016/S0140-6736(18)31999-8
Conforti, F., Pala, L., Bagnardi, V., De Pas, T., Martinetti, M., Viale, G., … Goldhirsch, A. (2018). Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis. Lancet Oncology, 19(6), 737-746. https://doi.org/10.1016/S1470-2045(18)30261-4
de Vicente, J. C., Rodriguez-Santamarta, T., Rodrigo, J. P., Blanco-Lorenzo, V., Allonca, E., & Garcia-Pedrero, J. M. (2019). PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma. Cancer Epidemiology, Biomarkers and Prevention, 28(3), 546-554. https://doi.org/10.1158/1055-9965.EPI-18-0779
Detre, S., Saclani Jotti, G., & Dowsett, M. (1995). A "quickscore" method for immunohistochemical semiquantitation: Validation for oestrogen receptor in breast carcinomas. Journal of Clinical Pathology, 48(9), 876-878. https://doi.org/10.1136/jcp.48.9.876
Dodson, A., Parry, S., Lissenberg-Witte, B., Haragan, A., Allen, D., O'Grady, A., … Thunnissen, E. (2019). External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. The Journal of Pathology: Clinical Research, 6(2), 138-145. https://doi.org/10.1002/cjp2.153
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., … Chen, L. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nature Medicine, 8(8), 793-800. https://doi.org/10.1038/nm730
Dudek, A. M., Martin, S., Garg, A. D., & Agostinis, P. (2013). Immature, semi-mature, and fully mature dendritic cells: Toward a DC-cancer cells interface that augments anticancer immunity. Frontiers in Immunology, 4, 438. https://doi.org/10.3389/fimmu.2013.00438
Ferris, R. L., Blumenschein, G. Jr, Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Gillison, M. L. (2016). Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine, 375(19), 1856-1867. https://doi.org/10.1056/NEJMoa1602252
Ferris, R. L., Blumenschein, G. Jr, Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., … Gillison, M. L. (2018). Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncology, 81, 45-51. https://doi.org/10.1016/j.oraloncology.2018.04.008
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., … Pages, F. (2014). Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. Journal of Pathology, 232(2), 199-209. https://doi.org/10.1002/path.4287
Gu, X., Boldrup, L., Coates, P. J., Fahraeus, R., Wang, L., Wilms, T., … Nylander, K. (2019). High immune cytolytic activity in tumor-free tongue tissue confers better prognosis in patients with squamous cell carcinoma of the oral tongue. The Journal of Pathology: Clinical Research, 5(4), 240-247. https://doi.org/10.1002/cjp2.138
Hanna, G. J., Woo, S. B., Li, Y. Y., Barletta, J. A., Hammerman, P. S., & Lorch, J. H. (2018). Tumor PD-L1 expression is associated with improved survival and lower recurrence risk in young women with oral cavity squamous cell carcinoma. International Journal of Oral and Maxillofacial Surgery, 47(5), 568-577. https://doi.org/10.1016/j.ijom.2017.09.006
Havel, J. J., Chowell, D., & Chan, T. A. (2019). The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nature Reviews Cancer, 19(3), 133-150. https://doi.org/10.1038/s41568-019-0116-x
Kim, H. R., Ha, S. J., Hong, M. H., Heo, S. J., Koh, Y. W., Choi, E. C., … Yoon, S. O. (2016). PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients. Scientific Reports, 6, 36956. https://doi.org/10.1038/srep36956
Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. Nature Reviews: Immunology, 16(10), 626-638. https://doi.org/10.1038/nri.2016.90
Krijgsman, D., Hokland, M., & Kuppen, P. J. K. (2018). The role of natural killer T cells in cancer-A phenotypical and functional approach. Frontiers in Immunology, 9, 367. https://doi.org/10.3389/fimmu.2018.00367
Leemans, C. R., Snijders, P. J. F., & Brakenhoff, R. H. (2018). The molecular landscape of head and neck cancer. Nature Reviews Cancer, 18(5), 269-282. https://doi.org/10.1038/nrc.2018.11
Lenouvel, D., Gonzalez-Moles, M. A., Talbaoui, A., Ramos-Garcia, P., Gonzalez-Ruiz, L., Ruiz-Avila, I., & Gil-Montoya, J. A. (2019). An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. Oral Diseases, 26(3), 511-526. https://doi.org/10.1111/odi.13088
Lin, Y. M., Sung, W. W., Hsieh, M. J., Tsai, S. C., Lai, H. W., Yang, S. M., … Chen, C. J. (2015). High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One, 10(11), e0142656. https://doi.org/10.1371/journal.pone.0142656
Lo Nigro, C., Denaro, N., Merlotti, A., & Merlano, M. (2017). Head and neck cancer: Improving outcomes with a multidisciplinary approach. Cancer Management and Research, 9, 363-371. https://doi.org/10.2147/CMAR.S115761
Lundqvist, L., Stenlund, H., Laurell, G., & Nylander, K. (2012). The importance of stromal inflammation in squamous cell carcinoma of the tongue. Journal of Oral Pathology and Medicine, 41(5), 379-383. https://doi.org/10.1111/j.1600-0714.2011.01107.x
Mattox, A. K., Lee, J., Westra, W. H., Pierce, R. H., Ghossein, R., Faquin, W. C., … Pai, S. I. (2017). PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs. Cancer Research, 77(22), 6365-6374. https://doi.org/10.1158/0008-5472.CAN-16-3453
Mehra, R., Seiwert, T. Y., Gupta, S., Weiss, J., Gluck, I., Eder, J. P., … Haddad, R. (2018). Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: Pooled analyses after long-term follow-up in KEYNOTE-012. British Journal of Cancer, 119(2), 153-159. https://doi.org/10.1038/s41416-018-0131-9
Moratin, J., Metzger, K., Safaltin, A., Herpel, E., Hoffmann, J., Freier, K., … Horn, D. (2019). Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma. Head and Neck, 41(8), 2484-2491. https://doi.org/10.1002/hed.25713
Muller, T., Braun, M., Dietrich, D., Aktekin, S., Hoft, S., Kristiansen, G., … Brossart, P. (2017). PD-L1: A novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget, 8(32), 52889-52900. https://doi.org/10.18632/oncotarget.17547
Naruse, T., Yanamoto, S., Okuyama, K., Ohmori, K., Tsuchihashi, H., Furukawa, K., … Umeda, M. (2019). Immunohistochemical study of PD-1/PD-L1 axis expression in oral tongue squamous cell carcinomas: Effect of neoadjuvant chemotherapy on local recurrence. Pathology Oncology Research, https://doi.org/10.1007/s12253-019-00606-3.
Ngamphaiboon, N., Chureemas, T., Siripoon, T., Arsa, L., Trachu, N., Jiarpinitnun, C., … Larbcharoensub, N. (2019). Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Medical Oncology, 36(2), 21. https://doi.org/10.1007/s12032-018-1241-1
Pardoll, D. M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer, 12(4), 252-264. https://doi.org/10.1038/nrc3239
Paul, S., Chhatar, S., Mishra, A., & Lal, G. (2019). Natural killer T cell activation increases iNOS(+)CD206(-) M1 macrophage and controls the growth of solid tumor. Journal for ImmunoTherapy of Cancer, 7(1), 208. https://doi.org/10.1186/s40425-019-0697-7
Polioudaki, H., Chantziou, A., Kalyvianaki, K., Malamos, P., Notas, G., Mavroudis, D., … Theodoropoulos, P. A. (2019). Nuclear localization of PD-L1: Artifact or reality? Cellular Oncology (Dordrecht), 42(2), 237-242. https://doi.org/10.1007/s13402-018-00419-7
Rasmussen, J. H., Lelkaitis, G., Hakansson, K., Vogelius, I. R., Johannesen, H. H., Fischer, B. M., … Friborg, J. (2019). Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. British Journal of Cancer, 120(10), 1003-1006. https://doi.org/10.1038/s41416-019-0449-y
Ratcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., … Walker, J. (2017). Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clinical Cancer Research, 23(14), 3585-3591. https://doi.org/10.1158/1078-0432.CCR-16-2375
Satgunaseelan, L., Gupta, R., Madore, J., Chia, N., Lum, T., Palme, C. E., … Clark, J. R. (2016). Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype. Pathology, 48(6), 574-580. https://doi.org/10.1016/j.pathol.2016.07.003
Schats, K. A., Van Vre, E. A., Boeckx, C., De Bie, M., Schrijvers, D. M., Neyns, B., … Kockx, M. M. (2018). Optimal evaluation of programmed death ligand-1 on tumor cells versus immune cells requires different detection methods. Archives of Pathology and Laboratory Medicine, 142(8), 982-991. https://doi.org/10.5858/arpa.2017-0159-OA
Sgaramella, N., Gu, X., Boldrup, L., Coates, P. J., Fahraeus, R., Califano, L., … Nylander, K. (2018). Searching for new targets and treatments in the battle against squamous cell carcinoma of the head and neck, with specific focus on tumours of the tongue. Current Topics in Medicinal Chemistry, 18(3), 214-218. https://doi.org/10.2174/1568026618666180116121624
Sturm, G., Finotello, F., Petitprez, F., Zhang, J. D., Baumbach, J., Fridman, W. H., … Aneichyk, T. (2019). Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics, 35(14), i436-i445. https://doi.org/10.1093/bioinformatics/btz363
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018). Regulation and function of the PD-L1 checkpoint. Immunity, 48(3), 434-452. https://doi.org/10.1016/j.immuni.2018.03.014
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016). Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nature Reviews Cancer, 16(5), 275-287. https://doi.org/10.1038/nrc.2016.36
Troeltzsch, M., Woodlock, T., Pianka, A., Otto, S., Troeltzsch, M., Ehrenfeld, M., & Knosel, T. (2017). Is there evidence for the presence and relevance of the PD-1/PD-L1 pathway in oral squamous cell carcinoma? Hints from an immunohistochemical study. Journal of Oral and Maxillofacial Surgery, 75(5), 969-977. https://doi.org/10.1016/j.joms.2016.11.006
Wallis, C. J. D., Butaney, M., Satkunasivam, R., Freedland, S. J., Patel, S. P., Hamid, O., … Klaassen, Z. (2019). Association of patient sex with efficacy of immune checkpoint inhibitors and overall survival in advanced cancers: A systematic review and meta-analysis. JAMA Oncology, 5(4), 529-536. https://doi.org/10.1001/jamaoncol.2018.5904
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018). Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery, 8(9), 1069-1086. https://doi.org/10.1158/2159-8290.CD-18-0367
Yang, F., Zeng, Z., Li, J., Zheng, Y., Wei, F., & Ren, X. (2018). PD-1/PD-L1 axis, rather than high-mobility group alarmins or CD8+ tumor-infiltrating lymphocytes, is associated with survival in head and neck squamous cell carcinoma patients who received surgical resection. Frontiers in Oncology, 8, 604. https://doi.org/10.3389/fonc.2018.00604
Yang, W. F., Wong, M. C. M., Thomson, P. J., Li, K. Y., & Su, Y. X. (2018). The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Oral Oncology, 86, 81-90. https://doi.org/10.1016/j.oraloncology.2018.09.016
Yoshida, S., Nagatsuka, H., Nakano, K., Kogashiwa, Y., Ebihara, Y., Yano, M., & Yasuda, M. (2018). Significance of PD-L1 expression in tongue cancer development. International Journal of Medical Sciences, 15(14), 1723-1730. https://doi.org/10.7150/ijms.27860